Aerie Pharmaceuticals, Inc. announced that on January 19, 2022, the company agreed with Thomas Mitro that he will no longer serve as the President and Chief Operating Officer of the Company as of February 28, 2022 (the Mitro Separation Date). Mitro will provide transitional services through the Mitro Separation Date. On January 19, 2022, the Company agreed with David Hollander that he will no longer serve as the Chief Research & Development Officer of the Company as of February 28, 2022 (the Hollander Separation Date).

Dr. Hollander will provide transitional services through the Hollander Separation Date.